These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Type 2 diabetes mellitus--guidelines for initiating insulin therapy.
    Author: Yeap BB.
    Journal: Aust Fam Physician; 2007 Jul; 36(7):549-53. PubMed ID: 17619673.
    Abstract:
    BACKGROUND: Insulin is often indicated for patients with suboptimally controlled type 2 diabetes mellitus, despite lifestyle modification and oral antidiabetic agents. OBJECTIVE: This article outlines the initiation of insulin therapy for patients with type 2 diabetes in the general practice context. DISCUSSION: Insulin initiation options are bed time basal insulin (NPH, glargine) 10 U for patients with fasting hyperglycaemia, or twice daily premixed insulin (eg. aspart 30%/NPH 70%) 6-10 U twice per day targeting day time or postprandial hyperglycaemia. Basal insulin should be titrated regularly on a prophylactic basis (eg. fasting glucose <4.4 mmol/L: -2U, 4.4-7.0: +0 U, 7.1-10.0: +2 U, >10.0: +4 U) or increased by 1 U/day until fasting glucose of 5.5 mmol/L is reached. HbA1c changes of -1.5 to -2.5% are achievable with potential weight gain around 3 kg over 6 months. Approximately 50% of patients can achieve HbA1c <or=7% with insulin doses around 40-70 U/day. Glitazones are an alternative to insulin, but for HbA1c, >or=9.5% insulin results in greater improvement in fasting glucose and HbA1c. Patients require education for blood glucose monitoring, healthy diet, exercise and identifying and responding to hypoglycaemia.
    [Abstract] [Full Text] [Related] [New Search]